Purpose Bone metastasis is an important factor for the treatment and prognosis of breast cancer patients. Whole-body bone scintigraphy (WBBS) can evaluate skeletal metastases, and 18 F-FDG PET/CT seems to exhibit high specificity and accuracy in detecting bone metastases. However, there is a limitation of 18 F-FDG PET in assessing sclerotic bone metastases because some lesions may be undetectable. Recent studies showed that 18 F-fluoride PET/CT is more sensitive than WBBS in detecting bone metastases. This study aims to evaluate the usefulness of 18 F-fluoride PET/CT by comparing it with WBBS and 18 F-FDG PET/CT in breast cancer patients with osteosclerotic skeletal metastases. Materials and Methods Nine breast cancer patients with suspected bone metastases (9 females; mean age ± SD, 55.6 ± 10.0 years) underwent 
Introduction
Breast cancer is the most common malignant tumor in women in the Western world [1] and is associated with a high incidence of skeletal metastases. Early detection and accurate assessment of bone involvement are required because skeletal metastasis is an important factor in treatment and prognosis. Conventional nuclear imaging to assess bone involvement is done by whole-body bone scintigraphy (WBBS) with 99m Tc-labeled polyphosphates [2] . WBBS using 99m Tc-methylene diphosphonate ( 99m Tc-MDP) and gamma cameras is highly sensitive and cost-effective, thus having contributed to the development and clinical spread of nuclear medicine imaging studies since the 1970s [3, 4] . Furthermore, 2-deoxy-2-( 18 F)fluoro-D-glucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) has recently emerged as an important tool for detecting breast cancer and skeletal metastases by providing functional and metabolic imaging of cancer with high spatial resolution [5] .
However, there have been few improvements in radiopharmaceuticals and gamma camera technology for WBBS during the past decades, and the supply of 99m Tc has become unstable because of the decrease in the number of active nuclear reactors in recent years [6] . 18 F-FDG PET/CT is sensitive for the detection of osteolytic bone metastases, but has limitations for the evaluation of osteosclerotic bone involvement due to low or absent activity in osteosclerotic metastases [7] . Therefore, new radiopharmaceuticals or imaging techniques to remove the drawback of WBBS and 18 F-FDG PET/CT are highly needed. 18 F-fluoride was widely used for bone scintigraphy after its introduction by Blau in the early 1960s [8] . However, some technical limitations of 18 F-fluoride and the widespread availability of 99 Mo/ 99m Tc generators encouraged the development of 99m Tc-labeled polyphosphates, though the pharmacokinetic properties of 18 F-fluoride are superior, resulting in higher bone uptake and faster blood clearance [9] . In the past decade, however, the availability of PET/CT scanners and cyclotron facilities has increased, and clinical interest in 18 F-fluoride for skeletal imaging has been renewed, with studies reporting the value of 18 F-fluoride PET/CT as a diagnostic tool for benign and malignant bone disease. In this study, we prospectively evaluated the usefulness of 18 F-fluoride PET/CT in Korean breast cancer patients with osteosclerotic bone metastasis by comparing WBBS, 18 F-FDG PET/CT and 18 F-fluoride PET/CT.
Materials and Methods

Patients
We prospectively enrolled nine breast cancer patients (9 females; mean age ± SD, 55.6 ± 10.0 years) with suspected skeletal metastases on follow-up WBBS or 18 F-FDG PET/ CT. All patients underwent WBBS, 18 F-FDG PET/CT and 18 F-fluoride PET/CT within an interval of 1 month. The clinical design of our study was approved by the Ajou University Institutional Review Board, and all patients gave informed consent to participate in the study.
All patients had clinical follow-up by blood tests and imaging studies after 18 F-fluoride PET/CT. The mean duration of follow-up was 14.3 ± 7.6 months (mean ± SD, range 3.4-26.5 months). They all were on antihormone therapy, and five patients received chemotherapy several months before 18 Ffluoride PET/CT. 18 
F-fluoride PET/CT
No specific pretreatment such as fasting or prohibiting parenteral infusion of sugar-containing fluids was required before PET/CT scanning. First 370 MBq of 18 F-fluoride was administered intravenously, and patients were asked to urinate just before scanning. Image acquisition started 60 min after intravenous injection. PET/CT images were acquired using the Discovery ST scanner (GE Healthcare, Milwaukee, WI, USA). Seven to eight frames (3 min/frame) of emission PET data were acquired in a three-dimensional mode after noncontrast CT scans from the base of the skull to the upper thigh (tube rotation time of 1 s/revolution, 120 kV, 60 mA, 7.5 mm/ rotation and acquisition time of 60.9 s for a scan length of 867 mm). Emission PET images were reconstructed with noncontrast CT using iterative reconstruction (ordered-subset expectation maximization with 2 iterations and 30 subsets, field of view 0 600 mm, slice thickness 0 3.27 mm). Attenuationcorrected PET/CT images were reviewed on the GE AW workstation (GE Healthcare). 18 
F-FDG PET/CT
Patients were fasted and prohibited from parenteral infusion of sugar-containing fluids at least 6 h before scanning. They were also asked not to undertake strenuous exercise for 1 day before the examination. Their blood glucose was measured before intravenous administration of 18 F-FDG to ensure a level of < 150 mg/dl. After injection of 370 MBq 18 F-FDG, all patients were instructed to rest comfortably for 60 min and empty their bladder just before scanning. PET/CT images were obtained using the same scanner and the same method as for 18 Ffluoride PET/CT. Attenuation-corrected PET/CT images were reviewed on the GE AW workstation (GE Healthcare). Standardized uptake value (SUV) was calculated based on the injected dose and the patient's body weight.
Whole Body Bone Scintigraphy WBBS was performed 4 h after injection of 740 MBq 99m Tc-MDP. Anterior and posterior view images were acquired using a double-headed gamma camera with lowenergy, high-resolution collimators (Infinia Hawkeye 4; GE Healthcare). Additional lateral or oblique view images were obtained when it was not possible to determine the exact location of increased uptake.
Image Interpretation and Analysis
Two nuclear medicine physicians interpreted WBBS, 18 Ffluoride PET/CT and 18 F-FDG PET/CT by visual analysis based on consensus. Focally increased 18 F-fluoride or 18 F-FDG uptake in bones (not in the joints or edges of vertebral bodies) on PET/CT fused images without evidence of degenerative or traumatic changes on CT images was interpreted as a putative metastasis. Osteosclerotic and osteolytic lesions were also classified by evaluating low-dose nonenhanced CT images of PET/CT. Abnormally increased uptake of 99m Tc-MDP on WBBS was categorized as a putative metastasis when it was not located around joints; involved the posterior aspect of the vertebral body and pedicle; or presented as an elongated shape in the ribs.
Lesion-based analysis was performed for all putative metastatic lesions on WBBS, 18 F-fluoride PET/CT and 18 F-FDG PET/CT. Each lesion was grouped into the five skeletal regions (skull, vertebral column, thoracic cage, pelvic bones and long bones of extremities). The ribs, manubrium, sternum, clavicle and scapula were included in thoracic cage region. For patient-based analysis, fiveregion analysis of the skeleton was applied to each patient.
The presence or absence of skeletal metastases in putative lesions that were shown on 18 F-fluoride PET/CT was determined by combining their clinical, imaging and histopathological results. Skeletal metastasis was confirmed if any of the following criteria were present: positive histopathology, other radiographic confirmation (MRI or CT) or progression of the skeletal lesion on subsequent imaging studies ( 18 F-FDG PET/CT or WBBS) in 12 months.
Results
Lesion-Based Analysis
Eighty-five putative metastatic lesions were detected on 18 Ffluoride PET/CT, whereas 24 and 31 lesions were found on 18 F-FDG PET/CT and WBBS, respectively (Table 1) . No abnormal uptake was recognized in the skull region on 18 F-FDG PET/CT and WBBS, but 18 F-fluoride PET/CT showed four lesions. Also 18 F-fluoride PET/CT identified five lesions in the long bones of the extremities that were not detected on 18 F-FDG PET/CT. All putative metastatic lesions on 18 F-FDG PET/CT and WBBS were identified on 18 F-fluoride PET/CT. Of the 85 putative metastases on 18 F-fluoride PET/CT, 37 lesions were at the vertebral column, 24 at the pelvic bones, 15 at the thoracic cage, 5 at the long bones of the extremities and 4 at the skull.
The presence or absence of skeletal metastasis in putative lesions on 18 F-fluoride PET/CT was determined by histopathology, radiographic study or progression of the skeletal lesion depending on the patient's condition (Table 2) . Of 52 true metastases, (Table 1) . Table 3 shows the number of true-positive, false-positive, false-negative and true-negative lesions detected on 18 F-fluoride PET/CT in the skeletal regions. All true metastatic lesions 
Patient-Based Analysis
Skeletal metastases of eight patients were correctly diagnosed with 18 F-fluoride PET/CT (7 with metastasis, 1 without metastasis). Eight patients showed putative metastasis on 18 F-fluoride PET/CT, but seven patients were confirmed to have skeletal metastasis. Patient 4 had a suspicious lesion in the vertebral column on WBBS, but no focal 18 F-fluoride uptake was found on PET/CT. The MRI and follow-up WBBS showed no bone metastasis. Table 2 shows the number of putative metastases detected on WBBS, 18 F-FDG PET/CT and 18 F-fluoride PET/CT, and the number of true metastases for each patient. The extent of bone metastasis was correctly estimated in three patients (patient 1, 3 and 4) and overestimated in the other six patients on 18 Ffluoride PET/CT. Five patients (patient 3, 5, 6, 8 and 9) were underestimated on WBBS and 18 F-FDG PET/CT.
Discussion
WBBS showed planar images, whereas PET/CT enabled evaluation of the region of radiopharmaceutical uptake by high spatial resolution. Moreover, tumor or functional imaging can be obtained by using suitable radiopharmaceuticals in PET/CT. The development of imaging technology and radiopharmaceuticals is currently in progress [9] . [10] . Therefore, the waiting time from injection of radiotracer to acquisition of images is less than 1 h in 18 F-fluoride PET/CT, but 3-4 h in 99m Tc-MDP WBBS [11] . 18 F-fluoride PET and 99m Tc-MDP WBBS are known to have no significant differences in radiation exposure. According to the reports of the 1999 and the 1987 International Commission on Radiologic Protection (ICRP), the effective dose after WBBS with injection of 518 MBq 99m Tc-MDP was 3.0 mSv, and after PET scan with injection of 148 MBq 18 F-fluoride was 4.0 mSv in a 70 kg adult [12, 13] . In the case of 18 F-fluoride PET/CT, the additional effective dose by CT scan should be considered. Though low-dose CT is applied, radiation less than 5 mSv is generated by CT scanning equipment. Therefore, radiation exposure of 18 F-fluoride PET/CT might be two or three times that of 99m Tc-MDP WBBS [14] . In the past decade, the clinical applications of 18 Ffluoride PET and PET/CT have been reported frequently. Several studies have demonstrated the utility of 18 F-fluoride PET/CT in detecting primary bone tumors and skeletal metastasis of several primary malignancies. Other reports claimed that 18 F-fluoride PET/CT can be used for the evaluation of benign disease such as unexplained bone pain, child abuse, osteomyelitis, trauma, degenerative arthritis, avascular bone necrosis, metabolic bone diseases and Paget's disease. They also showed that 18 F-fluoride PET/CT can predict bone viability after trauma or reconstructive surgery and complications after joint replacement operation [15] . Recently, the usefulness of 18 F-fluoride PET in malignant and benign bone disease in South Korea was reported, and the sensitivity and specificity for skeletal metastases in this study were 86 % and 88 %, respectively [16] .
The initial studies to compare the diagnostic performance of 99m Tc-MDP WBBS and 18 F-fluoride PET in the assessment of bone metastases have reported higher sensitivity, Interval, interval from first bone metastasis to 18 F-fluoride PET/CT; WBBS, whole body bone scintigraphy; FDG, 18 F-FDG PET/CT; Fluoride, 18 F-fluoride PET/CT specificity and accuracy of 18 F-fluoride [17] [18] [19] . According to a recent study, 18 F-fluoride PET/CT is more specific than 18 F-fluoride PET for evaluating skeletal metastases. Specificity of 18 F-fluoride PET and 18 F-fluoride PET/CT were 62 % and 100 %, respectively [20] . In the present study, 18 F-fluoride PET/CT found twice the number of putative metastases than 99m Tc-MDP WBBS (Table 1 ). This result was in accord with a recent study, which showed that 18 Ffluoride PET/CT has higher sensitivity (81 %) than WBBS (43 %) for assessing bone involvement in breast cancers [21] .
In the present study, 18 F-fluoride PET/CT detected the largest number of putative metastatic lesions in the vertebral column (37 lesions), followed by the pelvic bones (24), thoracic cage (15), long bones of the extremities (5) and skull (4) .
99m Tc-MDP WBBS and 18 F-FDG PET/CT showed the same order of skeletal regions. Also, this result was the same as that of previous reports evaluating skeletal metastases in breast cancer [22] .
On the contrary to our definition of putative metastasis on 18 F-fluoride PET/CT, we indicated the benign lesion as focally increased 18 F-fluoride uptake in joints, edges of vertebral bodies or bony lesions with evidence of degenerative or traumatic changes on corresponding CT images. All patients showed benign lesions except patient 1. Particularly, patient 4 had no putative metastatic lesions but four benign ones according to 18 F-fluoride uptake in the vertebral column, thoracic cage and long bones of the extremities; these were confirmed to have no metastases by MRI and follow-up WBBS. Three benign lesions of patient 6 (thoracic cage) and 8 (vertebral column) were demonstrated to have true metastases with follow-up 18 F-FDG PET/CT. Table 3 shows the number of true-positive, false-positive, false-negative and true-negative lesions detected on 18 Ffluoride PET/CT in skeletal regions. Of the 49 truepositive lesions, 20 lesions were at the vertebral column, 19 at the pelvic bones, 8 at the thoracic cage, 2 at the long bones of the extremities and 0 at the skull. There was a similar number of true-positive and false-positive lesions in skeletal regions of the vertebral column and thoracic cage, but about four times more true-positive lesions in the pelvic bones region. We could assume that 18 F-fluoride PET/CT may be helpful to determine skeletal metastasis in pelvic bones that is ambiguous on WBBS or 18 F-FDG PET/CT. Sensitivity, specificity, positive predictive value and negative predictive value of 18 F-fluoride PET/CT were 94.2 %, 46.3 %, 57.7 % and 91.2 %, respectively.
In the present study, the true metastasis was confirmed by histopathological or other radiographic examinations (MRI or CT). If the histopathological or other radiographic study was unavailable, the lesion was regarded as true metastasis when it showed progression with imaging follow-up ( 18 F-FDG PET/CT or WBBS) in 12 months. In fact, many putative metastatic lesions were determined by follow-up 18 F-FDG PET/CT performed 3-6 months later, not by histopathological confirmation or other radiographic studies (Table 2) . Therefore, 36 false-positive lesions on 18 F-fluoride PET/CT might include healed metastases on follow-up 18 F-FDG PET/CT or WBBS. In addition, 18 F-FDG PET/CT has limitations in detecting osteosclerotic metastases. We presumed that many false-positive lesions were healing and osteosclerotic metastases, and this is the reason for the lower specificity of the present study than in other related studies.
If we had enrolled pre-treated patients or performed more histopathological or other radiographic studies, the specificity might have been higher. A recent study that used full diagnostic CT or MRI as a gold standard reported that the specificity of 18 F-fluoride PET/CT was 68.3 % for breast cancer patients on antihormone therapy [21] . 18 F-FDG PET/CT has high sensitivity in the detection of osteolytic bone metastases, but has limitations in the evaluation of osteosclerotic bone involvement due to low or absent activity in osteosclerotic metastases [7] . However, 18 F-fluoride PET/CT is highly sensitive in detecting both osteosclerotic and osteolytic metastatic lesions [23, 24] . Withofs et al. reported the sensitivity of 18 F-fluoride PET/CT for detecting osteolytic and osteosclerotic lesions as 58.3 % and 90.9 %, respectively [21] . Many osteosclerotic lesions of true metastasis with increased 18 F-fluoride uptake showed no 18 F-FDG uptake ( Fig. 1) , so the counted number of osteosclerotic lesions on 18 F-fluoride PET/CT was about three times that seen on 18 F-FDG PET/CT (Table 4) . Moreover, one more osteolytic lesion without 18 F-FDG uptake was found on 18 F-fluoride PET/CT (Fig. 2, Table 4 ).
Metastatic bone lesions were of three types clinically: osteolytic, osteosclerotic and mixed type [25] . But purely osteosclerotic metastatic lesions were infrequently detected on CT images of PET/CT in the present study, so metastatic lesions showing any sclerotic change were classified as 'osteosclerotic,' and lesions with no osteosclerotic change were classified as 'osteolytic.' In other words, mixed metastatic lesions were included in the osteosclerotic metastatic lesions in the present study. If all osteosclerotic lesions that appeared on 18 F-FDG PET/CT were supposed to be mixed lesions, the ratio of 'pure osteosclerotic' to mixed lesions on 18 F-fluoride PET/CT might be 3:1.
It has been reported that the majority of patients with breast cancer have predominantly osteolytic lesions, whereas approximately 15 % to 20 % of them have osteosclerotic lesions [26] . However, the present study showed that most true metastatic lesions on 18 F-fluoride PET/CT (45/49, 91.8 %) and 18 F-FDG PET/CT (17/20, 85.0 %) were osteosclerotic (Table 4) . We assumed that the cause of this difference was the treatment with antihormone therapy or chemotherapy. According to the report by Yong Du et al., the majority of the osteolytic lesions became 18 F-FDG negative and gradually became osteosclerotic on CT after treatment, and sequential 18 F-FDG PET/CT studies revealed a gradual osteosclerotic process after effective treatment. This process seemed to be independent of the type of anticancer therapy [26] . All patients in the present study were diagnosed with skeletal metastases and continued to have treatment several months prior to 18 F-fluoride PET/CT ( Table 2 ). The treatment might influence the osteoclastic/osteoblastic process in metastatic lesions. This report by Yong Du et al. also accounts for the lower estimation of metastatic lesions by 18 F-FDG PET/CT than WBBS. Osteolytic metastatic lesions might be reduced by treatment and became 18 F-FDG negative. But increased osteosclerotic lesions might be detected by WBBS (Fig. 3) . Sensitivity and specificity of 18 F-FDG PET/CT were 38.5 % and 42.9 % and of WBBS were 48.1 % and 62.5 %, respectively, in the present study. We presumed that many true metastatic lesions were healing or were osteosclerotic metastases, and therefore 18 F-FDG PET/CT showed low sensitivity and specificity. The sensitivity and specificity of WBBS was in accord with a recent study for breast cancer patients on antihormone therapy (sensitivity 43.0 %, specificity 70.7 %) [21] .
One patient with many putative metastatic lesions on 18 Ffluoride PET/CT showed only a few lesions on 18 F-FDG PET/CT and 99m Tc-MDP WBBS. She underwent 18 F-FDG PET/CT 3 months later for follow-up, and many areas of 18 F-FDG uptake were found at the same locations of 18 Ffluoride PET/CT. This indicates that 18 F-fluoride PET/CT could help in the early detection of skeletal metastases. Of course, it was just one case and therefore has no statistical significance, but we tentatively suggest the possible utility of 18 F-fluoride PET/CT as a routine follow-up modality for the early detection of bone metastases in breast cancer.
The present study had limitations. First, the study enrolled only nine patients, and a larger patient cohort is required for the findings to have reliable statistical significance. The second limitation resulted from the method used to determine morphological changes of metastatic lesions. A previous report showed that morphological changes of skeletal metastatic lesions at low-dose CT components of PET/CT were observed in just half [27] . Our result may have a bias because only lowdose CT images of PET/CT were used to determine morphological characteristics in the present study. Lastly, choosing patients under anticancer therapy who were not not pre-treated and the few histopathological confirmations led to lower specificity than in other related studies.
Conclusion
18 F-fluoride PET/CT is superior to 99m Tc-MDP WBBS or 18 F-FDG PET/CT in detecting skeletal metastases, particularly osteosclerotic lesions in breast cancer patients. 18 Ffluoride PET/CT appears to have a role in the detection of bone metastases with high sensitivity and negative predictive value, which results in an effective treatment and good prognosis.
